Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q7Z4W2

UPID:
LYZL2_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q7Z4W2; Q6NZ69

BACKGROUND:
The Lysozyme-like protein 2, with its unique identifier Q7Z4W2, is part of an enzyme family that plays a pivotal role in the hydrolysis of bacterial cell walls. This protein's similarity to lysozymes indicates its potential involvement in the body's defense system against bacterial infections.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Lysozyme-like protein 2 could lead to groundbreaking advancements in medical treatments. Given its lysozyme-like properties, this protein could be instrumental in the creation of novel antibacterial therapies, offering new hope in the fight against resistant bacterial strains.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.